Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation

Steve N. Caritis; Shringi Sharma; Raman Venkataramanan; Gary D. Hankins; Menachem Miodovnik; Mary F. Hebert; Jason G. Umans; Thomas Benedetti; Donald Mattison; Anne Zajicek; Dawn Fischer; Aimee Jackson

doi:10.1016/j.ajog.2012.08.015

Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation

Steve N. Caritis
, Shringi Sharma
, Raman Venkataramanan
, Gary D. Hankins
, Menachem Miodovnik
, Mary F. Hebert
, Jason G. Umans
, Thomas Benedetti
, Donald Mattison
, Anne Zajicek
, Dawn Fischer
, Aimee Jackson

Research output: Contribution to journal › Article › peer-review

49 Scopus citations

Abstract

Objective: The purpose of this study was to estimate pharmacokinetic parameters and to evaluate placental transport of 17-hydroxyprogesterone caproate (17-OHPC) in singleton gestation. Study Design: Sixty-one women who received weekly injections of 17-OHPC underwent 2 pharmacokinetic studies at 20 + 0 to 24 + 6 weeks' gestation (study 1) and 31 + 0 to 34 + 6 weeks' gestation (study 2); daily blood samples were obtained between injections. In 18 women, blood samples were obtained over a 28-day period beyond the last injection (extended study). Maternal and/or cord blood were obtained at delivery. Results: The half-life (median ± SD) of 17-OHPC was 16.2 ± 6 days. Concentrations of 17-OHPC were higher during study 2 than during study 1. Body mass index affected maternal 17-OHPC concentrations. Cord:maternal 17-OHPC concentration ratios averaged 0.2; 17-OHPC was detectible in cord plasma 44 days after the last maternal injection. Conclusion: The apparent half-life of 17-OHPC is long, and pharmacokinetic parameters vary widely between subjects and are affected by maternal body mass index. The drug crosses the placental barrier.

Original language	English (US)
Pages (from-to)	398.e1-398.e8
Journal	American journal of obstetrics and gynecology
Volume	207
Issue number	5
DOIs	https://doi.org/10.1016/j.ajog.2012.08.015
State	Published - Nov 2012
Externally published	Yes

Keywords

cord blood
pharmacokinetics
placenta
preterm birth

ASJC Scopus subject areas

Obstetrics and Gynecology

Access to Document

10.1016/j.ajog.2012.08.015

Cite this

Caritis, S. N., Sharma, S., Venkataramanan, R., Hankins, G. D., Miodovnik, M., Hebert, M. F., Umans, J. G., Benedetti, T., Mattison, D., Zajicek, A., Fischer, D., & Jackson, A. (2012). Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation. American journal of obstetrics and gynecology, 207(5), 398.e1-398.e8. https://doi.org/10.1016/j.ajog.2012.08.015

Caritis, SN, Sharma, S, Venkataramanan, R, Hankins, GD, Miodovnik, M, Hebert, MF, Umans, JG, Benedetti, T, Mattison, D, Zajicek, A, Fischer, D & Jackson, A 2012, 'Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation', American journal of obstetrics and gynecology, vol. 207, no. 5, pp. 398.e1-398.e8. https://doi.org/10.1016/j.ajog.2012.08.015

@article{ab07c42737fc4548bb0f90c42c104229,

title = "Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation",

abstract = "Objective: The purpose of this study was to estimate pharmacokinetic parameters and to evaluate placental transport of 17-hydroxyprogesterone caproate (17-OHPC) in singleton gestation. Study Design: Sixty-one women who received weekly injections of 17-OHPC underwent 2 pharmacokinetic studies at 20 + 0 to 24 + 6 weeks' gestation (study 1) and 31 + 0 to 34 + 6 weeks' gestation (study 2); daily blood samples were obtained between injections. In 18 women, blood samples were obtained over a 28-day period beyond the last injection (extended study). Maternal and/or cord blood were obtained at delivery. Results: The half-life (median ± SD) of 17-OHPC was 16.2 ± 6 days. Concentrations of 17-OHPC were higher during study 2 than during study 1. Body mass index affected maternal 17-OHPC concentrations. Cord:maternal 17-OHPC concentration ratios averaged 0.2; 17-OHPC was detectible in cord plasma 44 days after the last maternal injection. Conclusion: The apparent half-life of 17-OHPC is long, and pharmacokinetic parameters vary widely between subjects and are affected by maternal body mass index. The drug crosses the placental barrier.",

keywords = "cord blood, pharmacokinetics, placenta, preterm birth",

author = "Caritis, \{Steve N.\} and Shringi Sharma and Raman Venkataramanan and Hankins, \{Gary D.\} and Menachem Miodovnik and Hebert, \{Mary F.\} and Umans, \{Jason G.\} and Thomas Benedetti and Donald Mattison and Anne Zajicek and Dawn Fischer and Aimee Jackson",

year = "2012",

month = nov,

doi = "10.1016/j.ajog.2012.08.015",

language = "English (US)",

volume = "207",

pages = "398.e1--398.e8",

journal = "American journal of obstetrics and gynecology",

issn = "0002-9378",

publisher = "Elsevier Inc.",

number = "5",

}

TY - JOUR

T1 - Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation

AU - Caritis, Steve N.

AU - Sharma, Shringi

AU - Venkataramanan, Raman

AU - Hankins, Gary D.

AU - Miodovnik, Menachem

AU - Hebert, Mary F.

AU - Umans, Jason G.

AU - Benedetti, Thomas

AU - Mattison, Donald

AU - Zajicek, Anne

AU - Fischer, Dawn

AU - Jackson, Aimee

PY - 2012/11

Y1 - 2012/11

N2 - Objective: The purpose of this study was to estimate pharmacokinetic parameters and to evaluate placental transport of 17-hydroxyprogesterone caproate (17-OHPC) in singleton gestation. Study Design: Sixty-one women who received weekly injections of 17-OHPC underwent 2 pharmacokinetic studies at 20 + 0 to 24 + 6 weeks' gestation (study 1) and 31 + 0 to 34 + 6 weeks' gestation (study 2); daily blood samples were obtained between injections. In 18 women, blood samples were obtained over a 28-day period beyond the last injection (extended study). Maternal and/or cord blood were obtained at delivery. Results: The half-life (median ± SD) of 17-OHPC was 16.2 ± 6 days. Concentrations of 17-OHPC were higher during study 2 than during study 1. Body mass index affected maternal 17-OHPC concentrations. Cord:maternal 17-OHPC concentration ratios averaged 0.2; 17-OHPC was detectible in cord plasma 44 days after the last maternal injection. Conclusion: The apparent half-life of 17-OHPC is long, and pharmacokinetic parameters vary widely between subjects and are affected by maternal body mass index. The drug crosses the placental barrier.

AB - Objective: The purpose of this study was to estimate pharmacokinetic parameters and to evaluate placental transport of 17-hydroxyprogesterone caproate (17-OHPC) in singleton gestation. Study Design: Sixty-one women who received weekly injections of 17-OHPC underwent 2 pharmacokinetic studies at 20 + 0 to 24 + 6 weeks' gestation (study 1) and 31 + 0 to 34 + 6 weeks' gestation (study 2); daily blood samples were obtained between injections. In 18 women, blood samples were obtained over a 28-day period beyond the last injection (extended study). Maternal and/or cord blood were obtained at delivery. Results: The half-life (median ± SD) of 17-OHPC was 16.2 ± 6 days. Concentrations of 17-OHPC were higher during study 2 than during study 1. Body mass index affected maternal 17-OHPC concentrations. Cord:maternal 17-OHPC concentration ratios averaged 0.2; 17-OHPC was detectible in cord plasma 44 days after the last maternal injection. Conclusion: The apparent half-life of 17-OHPC is long, and pharmacokinetic parameters vary widely between subjects and are affected by maternal body mass index. The drug crosses the placental barrier.

KW - cord blood

KW - pharmacokinetics

KW - placenta

KW - preterm birth

UR - https://www.scopus.com/pages/publications/84868156082

UR - https://www.scopus.com/pages/publications/84868156082#tab=citedBy

U2 - 10.1016/j.ajog.2012.08.015

DO - 10.1016/j.ajog.2012.08.015

M3 - Article

C2 - 22967833

AN - SCOPUS:84868156082

SN - 0002-9378

VL - 207

SP - 398.e1-398.e8

JO - American journal of obstetrics and gynecology

JF - American journal of obstetrics and gynecology

IS - 5

ER -

Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this